RecruitingNCT07713537

Risk Score of Embolism in Patients With AF Undergoing DOAC Therapy

Risk Score of Embolism in Patients With Atrial Fibrillation (AF) Undergoing Treatment With Direct Oral Anticoagulant (DOAC)


Sponsor

Hospital Universitari Vall d'Hebron Research Institute

Enrollment

250 participants

Start Date

Jan 1, 2025

Study Type

OBSERVATIONAL

Conditions

Summary

Acute ischaemic strokes occur despite the use of direct oral anticoagulants (DOACs). Evidence-based scale is necessary to assess ischemic stroke risk in atrial fibrillation (AF) patients.


Eligibility

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying DOAC Level for people with atrial fibrillation (af) and ischemic stroke. The study is currently recruiting participants at 2 locations.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERDOAC Level

Testing for plasma DOAC level concentration to determine 'on-therapy' status


Locations(2)

Germans Trias University Hospital

Barcelona, Barcelona, Spain

Vall d'Hebron University Hospital

Barcelona, Barcelona, Spain

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07713537


Related Trials